|
|
| Rodrigues,T.A.; Sampaio Junior,A.J.B.; Nunes,I.D.P.; Cartágenes,M.S.S.; Garcia,J.B.S.. |
| Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis, with proven effects of decreasing the risk of fractures and an indication of reducing the progression of osteoarthritis (OA). This study aimed to investigate the effects of SrRan as either a prophylactic or a treatment drug, using an OA rat model to assess pain behavior. A monoiodoacetate (MIA)-induced knee joint OA model in Wistar rats was used. Thirty Wistar rats (both sexes, 60 days old) were distributed in five groups of 6 rats each: the control group, that received no intervention; a prophylactic group, that received oral administration of 25 mg·kg-1·day-1 of SrRan for 28 days before induction of OA; a group treated with 25 mg·kg-1·day-1 of SrRan for 28 days after OA... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Osteoarthritis; Strontium ranelate; Pain; Treatment; Prophylaxis. |
| Ano: 2017 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000900602 |
| |
